Skip to main content

Table 3 Meta-analysis of AXIN2 rs2240308 polymorphisms and cancer risk

From: AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis

Group N

G vs. A

GA vs.AA

GG vs.AA

GG + GA vs.AA

GG vs.GA + AA

OR(95 % CI)

I 2â–˛

P Q â–˛

OR(95 % CI)

I 2

P Q

OR(95 % CI)

I 2

P Q

OR(9 % CI)

I 2

P Q

OR(95 % CI)

I 2

P Q

Overall

10

1.21(1.05–1.40)

39.5

0.094

1.00(0.81–1.14)

12.1

0.332

1.30(1.04–1.63)

35.9

0.121

1.10(0.91–1.42)

27.6

0.362

1.36(1.17–1.58)

19.5

0.263

Ethnicity

Asian

6

1.32(1.15–1.50)

0.0

0.641

1.11(0.82–1.48)

23.8

0.255

1.54(1.14–2.09)

0.0

0.407

1.32(0.98–1.76)

4.3

0.389

1.48(1.24–1.77)

0.0

0.507

Caucasian

4

1.08(0.83–1.40)

53.7

0.091

0.89(0.65–1.22)

0.0

0.439

1.01(0.71–1.43)

50.8

0.107

0.93(0.69–1.24)

31.0

0.226

1.14(0.88–1.48)

31.2

0.225

Cancer type

LC

3

1.36(1.17–1.59)

0.0

0.398

1.43(1.01–2.03)

16.2

0.303

1.93(1.36–2.75)

36.8

0.206

1.65(1.18–2.30)

32.0

0.230

1.45(1.18–1.79)

0.0

0.655

PC

2

1.20(0.89–1.62)

63.2

0.099

0.61(0.33–1.11)

0.0

0.587

1.00(0.53–1.85)

0.0

0.509

0.78(0.44–1.38)

0.0

0.872

1.58(0.76–3.28)

67.8

0.078

others

5

0.97(0.83–1.15)

7.3

0.362

0.80(0.60–1.07)

0.0

0.868

0.95(0.67–1.35)

0.0

0.762

0.83(0.63–1.10)

0.0

0.968

1.16(0.91–1.49)

14.5

0.322

Genotyping method

PCR–RFLP

6

1.25(1.06–1.48)

14.2

0.323

1.09(0.77–1.54)

22.8

0.263

1.48(1.04–2.10)

38.3

0.151

1.23(0.89–1.71)

37.8

0.154

1.40(1.11–1.76)

0.0

0.784

others

4

1.08(0.80–1.46)

65.2

0.013

0.89(0.68–1.16)

12.5

0.330

1.17(0.87–1.57)

41.9

0.160

0.97(0.75–1.24)

20.9

0.285

1.31(0.86–2.00)

65.8

0.034

Source of control

HB

6

1.11(0.95–1.29)

52.1

0.064

0.80(0.60–1.05)

0.0

0.397

1.02(0.74–1.42)

22.9

0.258

0.86(0.66–1.12)

0.0

0.309

1.29(1.02–1.63)

49.5

0.078

PB

4

1.28(1.11–1.48)

0.0

0.461

1.22(0.88–1.68)

14.9

0.317

1.61(1.17–2.23)

27.5

0.247

1.39(1.03–1.89)

27.2

0.249

1.38(1.14–1.68)

0.0

0.749

Score ≥ 10

8

1.23(1.05–1.45)

46.8

0.069

1.03(0.82–1.30)

24.6

0.233

1.35(1.06–1.71)

34.6

0.178

1.15(0.93–1.42)

37.7

0.129

1.36(1.17–1.59)

29.1

0.191

  1. N number of studies, OR odds ratio, CI confidence interval, PQ chi–squared Q test value, LC lung cancer, PC prostate cancer; others(colorectal cancer. head and neck cancer, astrocytoma, Ovarian cancer, papillary thyroid carcinoma), PCR–RFLP Polymerase chain reaction-restriction fragment length polymorphism, HB Hospital based, PB Population-based, Score quality scores
  2. ▲ I 2(%); If P Q  < 0.1 or I 2 ≥ 50 %, using a random-effects model; If P Q  ≥ 0.1 or I 2 < 50 %,using a fixed- effects model